Objective:

To compare the efficacy, safety, and patient outcomes of dexmedetomidine versus midazolam-fentanyl for sedation and analgesia in surgical patients.

Approach:

Key Findings:

• Dexmedetomidine significantly lowered mean arterial pressure (MAP) by −6.42 mmHg.
• After excluding an outlier, dexmedetomidine reduced heart rates by 6.71 bpm.
• No significant differences in respiratory rate and oxygen saturation between groups.
• Adverse events were comparable between dexmedetomidine and midazolam-fentanyl.

Interpretation:

Dexmedetomidine provides better blood pressure control compared to midazolam-fentanyl while maintaining similar safety profiles for respiratory parameters.

Limitations:

• Only 4 RCTs with 259 patients were included.
• Sensitivity analyses may not fully address all sources of bias.
• Long-term outcomes such as postoperative delirium were not assessed.

Conclusion:

Dexmedetomidine is a promising alternative to midazolam-fentanyl for sedation during surgery, warranting further research on long-term outcomes.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.